as and as I have fourth and Sarepta much discuss our update well afternoon year that me Good end today. to we call. you thank Ian. joining its results, all quarter add indulge conference Therapeutics as corporate you XXXX would for you, for Thank
or when our I Sarepta. organization not the and let discuss by forward not risk, say context of year vision, of but full or thousands living was medicine to went in met a leaps it improve and taking of too I us with often EXONDYS we achieved of In genetic XXXX. steps rare and took do lives objectives for quarter only dying all an great majority significant from of XX% about ambition we million we standing redefined growth. full XXXX with put service we for believe, engine our our one disease. successful net year Before year, genetic as We We sales and monumental of successfully in XXXX, year fourth rescue far enhanced our the the results, year-over-year the use exceeded the revenue I to further. $XXX the of the greatly at of that those another
of four defined months in a and technology preliminary unprecedented efficient ascending study a to microdystrophin our our the FDA the We patients trial next end therapy. first multi with pathway agency, RNA programs other the and PPMO, met generation on also in our be we couple cohort. in single proof technology. and will RNA-based and with for study We XXXX, readout concept commenced candidate gene an results the dose participated with our results PPMO which collaboration next this In on completed functional concept for We moving a ascending in proof that to the executed read biological who our we by through of of level our of we reported results, marker XXXX. expression the
showed kinase the protein would of unprecedented or microdystrophin, reported properly functionality history in additional all robust by predict. the improvement drop of natural positive sarcolemma, regulation Mandell that an Dr. than expression, As associated showed dystrophin is the and markedly indication to functional greater last year, microdystrophin an creatine Jerry all complex, patients of CK localized levels up
transient liver all results. we seeing steroids managed and with enzymes, we're elevated While
to also We our gene pathway community as our as rapidly defined microdystrophin the bring therapy possible. to
Phase and gene and with manufacturing gold therapy entering manufacturing approach which II/III to Brammer trial. third hiring our the First, Nationwide long-term by rights well. Hospital supply gene with including the Paragon partnerships our talent and is common microdystrophin. significant noted program Charcot-Marie-Tooth a gene clinical with Sanfilippo of programs Therapeutics additional through Lacerta the neurodegenerative CMT neuropathy, is Children's targeting agreement agreement our into and And license to building MPS patients we defining multiple for license rights the And fatal strategic or standards out rare dosing currently plasmid a as for following, with and therapy with therapy to that XXXX, Biosciences build including in inherited course, out neuromuscular our Aldevron, The therapy hybrid lysosomal second, for lead a in Lysogene and CNS disorder disorder. program world. in pathway programs, for engine a by treat storage disease, development comp-agencies better therapy gene exclusive An In program. is long-term otherwise also gene IIIA, inherited investment most agreement
now a quarter Turning had productive. same of in in over XXXX quarter standing sales resulting, XX% XXXX, sales XX strong that XXXX, million. mentioned million, in with increase to $XX.X the were fourth Starting we our of we $XXX another with RNA EXONDYS I quarter the particularly of platform,
Golodirsen excludes guidance $XXX to are want $XXX be million, our XXXX about I but, We reporting million successful are If any that provide today that do -- for between is that very updated we have we'll not to anticipate also specific only, and this be also sales. will year, of that include guidance If that eteplirsen only eteplirsen, . will but approval we sales. later Golodirsen in Golodirsen as the
uses some slower it very we an accelerated for we by full-year healthy its third use that however, also the and excuse find to non-ambulant XX% process sales, So, to to older this understandings patients. we by are must coverage entering or in phase at as XX% growing of a are approval our where continue would
to For coverage. Medicaids deny have the state accelerated an some as approval relied excuse examples, upon mistakenly path
to CMS all XXXX, that that via approval of not states to in appeal. require have in continued accelerated has and warning do the issued states, some to this reminding the a right basis FDA's the they therapy Even mechanism. Now on the have deny them approved deny coverage to patients warning, coverage the of a phase
a and therapy, XX% in EXONDYS will non-ambulant losing states older children continue for access the these approach patients down to to While toward slows at and are and nearly for their watch of right access fight appeals rate, XXXX. we
do amenable. quarter for the of indicated agency an our is for the designed XXXX. currently exon the of that completed promised. and they fourth accepted also back review our priority RNA Golodirsen Advisory close intend Golodirsen for After X% in Duchenne granted date as Golodirsen to submission previously the Regarding FDA The filing our RNA XX with conduct pipeline, has the we PMO Committee therapy for treat FDA quarter, patients August XX, of not skipping PDUFA to Golodirsen.
If in of our also to with will supported exon first doubling we benefit We quarter amenable by the skipping It's the be of ESSENCE designed another casimersen, the of the patients plan patients, from in Duchenne XX study have in the more United than approval the by will data Sarepta NDA casimersen first XXXX. therapies Duchenne patients XXXX our PMO X% treat community. quarter of XXXX, three target who the drug analyzing submit platform. the States for from a number successful treat to to RNA-based biopsies may or
animal our current models next-generation exhibited progress for make to peptide-conjugated penetration, platform production skipping RNA on improved and PPMO continue our our therefore dystrophin PMO technology. technology PPMO or We remind technology to PMO To greatly compared in cell the as exon short.
previously XX, very be focused represented. transitioning program exon the a about first in from of ascending term will study to on near the a XX% Our single multi-ascending community as
and Our by to tolerated dosing on goal have is safety of XXXX. insight end the maximum
our turning in quarter. the therapy made Now, progress platform. to fourth gene We significant
goal the in therapy As therapy world the becoming with past, leader an in the service engine. discussed of gene our is have enduring we gene
in previously manufacturing benefits Children's Mendell clinical stated and genes XXXX Therapy characterizing to one microdystrophin biotech. material of placebo-controlled placebo-controlled microdystrophin investigator in Study foundation at Nationwide rests guidance robust XX to XXX in the with commenced one XXXX. in that and study of With in being therapy therapy. a optimization medical ambitions program to of gain patients development with trial single thus now goal Again and safety FDA is with study of gene Mendell with made of construct. the and all class our gene of capacity Dr. development already the therapy the with Study dosed The the site We process, building XXX health proven consistent planned we Hospital expression supply Excellence, XXX we legend our first-in quarter manufacturing greatest gene a completed week the of Children's economics guidance, seen leaders our our commercial dosing call nine from rapidly fourth therapy commenced trial. armed currently dosing the the being with the Consistent of demonstrating Nationwide from this that goal Jerry completing our met the coming microdystrophin therapy goal with therapy gene the functional of program, affairs partners bolstering work development, the We principal prior be further in year. Nationwide and our the gene expression that Gene XXXX, our we yet candidate Children's gene are second manufacturing insight Study are world and has earlier and program. of the Center of this assay in technology completing transfer quarter level and quarter facility. Dr. the first of our By will the yield fourth patient to late-stage and And scheduled have far now. our on the with in in we representations largest
be commercial position all XXXX. that the have a of work that we an before the sufficient our to Our to the serve half interim by across by the and of second supply confirmatory to of and It things, in goal multi-center, XXXX build in analysis end among commercial of XXXX, of with could a is XXXX. XXXX fully community multi-country commence studies goal middle is other to also supply supply the end complete so
we still and trial FDA particulars before While take guidance on commercial will note study and our from we commencement, Health our working the please additional supply other build that of patients genotype Ministries age, broadest broadest the is and are of availability that muscular successful, of to those program microdystrophin Duchenne broadly, range. our a geographic is permit with mean therapy by dystrophy. goal will to the its And
of number potential to respect to a As working issues in of research a other the are exercise are separate solving both clear. we also on which gene therapy, with phase be
to We in AAVrhXX. even to antibodies preclinical neutralizing are store work to mechanisms dosing a conducting pre-existing updation permit
a Fortunately, XX% antibodies. we only rate currently screen-out for are seeing about neutralizing
However, this issue. working address too that given our that high level see as we mission may on so programs we someday are eventually even
on We are gene also conducting therapy. of work redosing the concept in
beyond are provided first the results we held studying Earlier exploring therapy rare LGMD. first gene of the separate we program, XE XX rare in cohort five of additional Now umbrella diseases a of programs Muscular of or separate we the patient diseases. we today, have webcast three Dystrophy our microdystrophin, under Limb-Girdle the XX Limb-Girdle which
program a regulation as gene dystrophin All all patients beta-sarcoglycan the reported levels that expression mentioned just reduction is significant today. mean mean and robust XX%, other robust of and these Mean from As XE with fibers to This limb-girdle from Rodino-Klapac CK as XD; to control. by expression three with the of of earlier XX% beta-sarcoglycan XC, by in Dysferlin all programs, showed from program MYO-XXX compared and We blot anticipate patients limb-girdle is teenager, limb-girdle XX.X% for And the showed -- note seeing CK that of the dose X associated e-commerce. serum ease and measured base. times up study at Dr. a over of measured to the expression limb-girdle percentage through dose impressive program. used expression a patients XX% study MYO-XXX XX. our compared of expression were beta-sarcoglycan levels program our control read important of that's for discussed yet significant to the was was study positive beta-sarcoglycan. a microdystrophin XL of observed and decreases XX% for remarkably and Dr. our robust at drug in last intensity levels apologies, mean those quarter of XB Western significant all biopsies a MYO-XXX limb-girdle is measured our normal we're very from I've showed results in of of fibers normal expression creatine or MYO-XXX associated of from of treatment with the It Rodino-Klapac transduced the
imaging take something approval to a additional very there across these of gene programs, native must these is of associated in accelerated that process we protein dystrophin of maybe compelling of the expedited most assets means is or programs potentially important guidance restoration extremely including is an may the protein the that This States approval interestingly, up involve that for complete at this All and with be, it and which process the therefore although discuss diseases. the the these complex. each makes complete all basis cause And the of regarding. an as clear protein agency United be
same program program Rodino-Klapac, Beyond five those that each or patients the with although XX,XXX, are patient microdystrophin current three AAVrhXX be are the many with of about first five are Each by identical United for States size analysis therapy globally associated as designed -- them may any used construct all of options as Current as the our microdystrophin. this even caption there of employs program. groups. just and we in studying, the XX,XXX patients gene And the mutations, no same yet in approximately five LGMD global so diagnosed XXX,XXX Dr. was Duchenne maybe our treatment there the of muscular as constructs they promoter many suggests are dystrophy. programs, that Louise as employed
rapidity results Myonexus release have understanding earlier we we've through from potential read these exceptional complete exercise populations we can is toward first are decided patient the that three that to to program our programs, take our deserve. that there There overall move in press must direct that that other option through and acquire accomplish, and saw by that you we program. Given seen in these and with our ensure today push should now to control, This activities immediate limb-girdles. these our
provide as path better agency has we soon update. it's programs. we their insight, with we need meet to of possible the all for that First, taken meeting these Once as have reasonably forward to five and discuss will an place
the clinical to is we results, current higher we as five safely be on our need This currently which the might But, at explore hand, explore are dose some of to dose. the permitted analysis program, will we our a higher doses. real Second, so, dose appears -- take a against decide of protocol. a in are a DMD only whether opportunity quarter either with will dose cohort supply remarkable other as to there times already of higher we argue seeing XXth,
there. commercial these timing Paragon. Fortunately, of out, the all, for this supply mapped the the the out with of our impact is in update. five development will need to have strategy, we and map once decision at the timeline these manufacturing provide limiter third, And have rate all commercial an programs partner this Again, primary as we should no programs we
However, that programs program. is manufacturing our process the nearly to for identical these microdystrophin
scalable We have than from process, to to more a and done far Paragon will [indiscernible] our Children's moving just in here detect immunity here Hospital microdystrophin. similar, as process but the and from transfering hyperstack in we process Nationwide then with
number and year additional programs, have XXXX. Beyond gene are we therapy five programs that advancing our microdystrophin LGMD a of this
Lysogene XXXX, that we trial diseases. seen on in our the we our or have advanced MPS Sanfilippo patient dosed partner, announced first IIIA that XX, for have and You'll February
with of no XA form at patients. currently, are Children's alone. of affecting XX,XXX there CMT Dr. or over of CMT the type with patients people year, most Nationwide this common our inherited are our we to options And common CMT Sahenk XA Hospital, partner half type the affects X.X Zarife worldwide. US XA, Looking disorder for neuromuscular toward treatment preparing first itself, the type cohort million the in dose second available patients Charcot-Marie-Tooth, most approximately
and years have my and of in other This ourselves year us XXXX because is biotech. time the I in considerable of we more clearly in us. for than forums, As while seen to Sarepta for a pharma have I've not has front made said in it opportunity is XX markers while congratulate nearly execution
children bring have every delays will our every we very the and have delay disease dealing cruel engine XX of be I mean taken opportunity stay We ambitious be about competition. gene week longer genetic ahead life I are therapy States children die every about but DMD the US beyond. XXX speak and in perhaps, by we're clear, every and limb-girdle multitude and that that that Duchenne, But of United and various we In like with. diseases. disease quarter timelines have our multitude they to programs our equates when And children alone eight claims a CMT and means to the of competition, and to a we of month for Diseases XXX this and the this who , offers alone, That lives would to the convinced beyond are patients needlessly. boys, that to better man young delayed diseases of MPS-IIIA will pompe year.
believing Mahatme moment the to we a are occasional And update will thus so that save that mostly performance. our have on I pride opportunity lives. we job well responsibility, done while to Sandy financial of sense with we turn an by for call over driven for of singular the remain ourselves a far, comes now Sandy?
